Phio Pharmaceuticals Corp PHIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHIO is a good fit for your portfolio.
News
-
Phio Pharmaceuticals Secures New Investor
-
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
-
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
-
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
-
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
-
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
-
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
-
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Trading Information
- Previous Close Price
- $0.76
- Day Range
- $0.73–0.76
- 52-Week Range
- $0.55–3.39
- Bid/Ask
- $0.73 / $0.76
- Market Cap
- $3.44 Mil
- Volume/Avg
- 27,649 / 259,903
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.phiopharma.com
Valuation
|
Metric
|
PHIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PHIO
Financial Strength
|
Metric
|
PHIO
|
|---|---|
Quick Ratio | 5.18 |
Current Ratio | 5.48 |
Interest Coverage | — |
Quick Ratio
PHIO
Profitability
|
Metric
|
PHIO
|
|---|---|
Return on Assets (Normalized) | −94.52% |
Return on Equity (Normalized) | −119.54% |
Return on Invested Capital (Normalized) | −118.45% |
Return on Assets
PHIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Yfdnpjnkl | Ykzzqwt | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hprpblwr | Rzrvh | $111.3 Bil | |||
| Moderna Inc
MRNA
| Gpyfgnzfq | Fjwz | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Fwxjxnjn | Gyk | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Xfnxrffqc | Lnh | $22.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Drxvhllp | Pmhgsr | $19.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rcwpmhk | Wwwsyx | $15.3 Bil | |||
| Incyte Corp
INCY
| Vfktngtt | Yqgtnz | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bgwpgfkb | Qpyfkt | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Gzhytpxw | Ryl | $12.2 Bil |